New Amsterdam Partners’s Impax Laboratories, Inc. IPXL Stock Holding History

New Amsterdam Partners’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-276,784	Closed	-$8.86M	–	151
2016 Q1	$8.86M	Buy	+276,784	New	+$9.73M	0.93%	41
2015 Q2	–	Sell	-224,754	Closed	-$10.5M	–	138
2015 Q1	$10.5M	Sell	224,754 -51,415	-19%	-$2.05M	0.85%	45
2014 Q4	$8.75M	Sell	276,169 -497,923	-64%	-$14.6M	0.76%	45
2014 Q3	$18.4M	Buy	774,092 +78,992	+11%	+$2.02M	1.23%	34
2014 Q2	$20.8M	Buy	+695,100	New	+$18.8M	1.36%	29

Other funds holding IPXL

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return

PCM

Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

New Amsterdam Partners's IPXL Position: Q2 2016 in Review

New Amsterdam Partners sold out of Impax Laboratories, Inc. (IPXL) in Q2 2016, closing a stake of 276,784 shares — an estimated $8.86M sold.

New Amsterdam Partners first reported a position in IPXL in Q2 2014 and held it in 5 quarters. The position peaked at $20.8M in Q2 2014. 198 funds tracked by Wall St. Rank hold IPXL as of Q2 2016.

New Amsterdam Partners reported no remaining Impax Laboratories, Inc. position as of Q2 2016 after selling out during the quarter.
New Amsterdam Partners sold 276,784 Impax Laboratories, Inc. shares in Q2 2016, an estimated $8.86M.
New Amsterdam Partners first reported a position in Impax Laboratories, Inc. in Q2 2014 and held it in 5 quarters.
New Amsterdam Partners's Impax Laboratories, Inc. position peaked at $20.8M in Q2 2014.
198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2016.

Based on New Amsterdam Partners's 13F filing for Q2 2016, filed 1 Aug 2016.